Crane Company
CRCrane Company is printing record margins on a fuller multiple. From here the earnings must do all the lifting.
Biggest watch item: margins are the best this company has ever printed — every ratio flatters at record profitability, so the whole story leans on margins holding.
The price is in a confirmed uptrend (16 weeks in) while the P/E sits at the 69th percentile of its own 4-year range. Underneath, the last four quarters read deteriorating — profit −12.5% year on year, and 60% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Crane Company trades at $197, in a confirmed uptrend and 16 weeks into that stage. That is +0.6% against its own 200-day average. It sits at 53% of a 52-week range of $164 to $226. On relative strength it is currently behind the S&P 500 on a trailing-13-week view (2 weeks and counting).
Today the stock is in a confirmed uptrend — week 16 of stage 2. At $197 it trades +0.6% versus its 200-day average and sits at 53% of its 52-week range ($164–$226).
Against the market, two honest reads. Cumulative: over the last 3.5 years the stock moved +164% while the S&P 500 moved +84% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (2 weeks and counting; last ahead the week of 2026-09-04) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
Crane Company trades at 34.4× P/E, mid-range by its own standards (69th percentile). Its long-run median P/E is 31.6×, measured across 3.5 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 34.4× is mid-range by its own standards (69th percentile), against a long-run median of 31.6× measured over 3.5 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +24.0% against a +8.3% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 3y, of the +31.4%/yr price move, ~+19.2%/yr came from earnings growth and ~+12.2 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Topping out Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Crane Company reads as topping out on its fundamental arc. Topping out — profit and EPS growth have decelerated hard (profit growth +97.4% at its peak → +10.3% latest) while ROCE still reads 15.3%. The read is built from 12 quarters across 4 curves, on full evidence.
Why it matters: decelerating from a peak is where good stories quietly end — the multiple usually notices late.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +8.5% | +9.1% | — | — |
| Profit | +22.2% | +24.7% | — | — |
| EPS | +24.0% | −3.7% | — | — |
| Stock price | +8.3% | +31.4% | — | — |
4-Factor Sector Score
47.0/100 — rank 17 of 30 in Specialty Industrial Machinery · 58% evidence confidence
Crane Company scores 47.0 out of 100 against the 30 companies it is compared with in Specialty Industrial Machinery, ranking 17. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 14 + 10.8 + 9.3 + 12.9 = 47. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Crane Company reported $0.7 B of revenue in the Mar 26 quarter, +25.0% year on year. That is the 8th straight quarter of year-on-year growth. Over 4 years it has compounded at 2.9% a year. The last full year, FY25, came in at $2.3 B. The last four reported quarters add to $2.5 B.
FY25 revenue came in at $2.3 B (+8.5% on the year), capping 4 years at 2.9% compound. The latest quarter (Mar 26) printed $0.7 B, +25.0% year on year — the 8th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +12.3% growth against the decade's 2.9% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +12.4% over the last 4 quarters against +8.5%/yr over the last 8 — accelerating; TTM profit +10.3% vs +23.4%/yr — rolling over.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Crane Company's operating margin is 14.3% in the Mar 26 quarter, −3.6 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 5 fiscal years the operating margin has ranged 0.6% to 18.2%. The current quarter sits inside that band.
The latest quarter's operating margin is 14.3%, −3.6 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged 0.6%–18.2%, and FY25's 18.2% is the top of that band — a record year.
🚨 Why the margin moved: operating margin went −3.6 pp year on year while gross margin went −2.9 pp — the loss came mostly from the gross line: input costs and pricing.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Crane Company earned $0.1 B of net profit in the Mar 26 quarter, −12.5% year on year. Full-year FY25 profit was $0.3 B. The 4-year compound rate is 13.3%. That is 10.0% of the quarter's revenue. The same quarter a year earlier earned $0.1 B.
Mar 26 profit was $0.1 B, −12.5% year on year. On the full year, FY25 printed $0.3 B (+22.2%), and the 4-year compound rate is 13.3%.
🚨 Why profit moved: revenue contributed +25.0% and the margin −3.6 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit +11.2% vs revenue +12.3%. Profit and revenue are moving roughly in step.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 60% of Crane Company's reported profit arrived as operating cash — most of the profit is real cash. In FY25 that was $0.4 B of operating cash against $0.3 B of profit. After $0.1 B of capital spending, $0.3 B was left as free cash.
FY25: operating cash of $0.4 B against reported profit of $0.3 B, leaving free cash of $0.3 B after $0.1 B of capital spending. Across the last 3 fiscal years the conversion rate is 60% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
🚨 Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Crane Company does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $0.0 B over the last 3 years. Averaged over those years that is 0.0% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $0.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
Crane Company earns a ROE of 16% in FY25. That is up from a trough of 9% in FY22. Return on invested capital clears the cost of that capital by +7.7 percentage points, so growth here adds value rather than only size. The wiring behind it is 14.3% net margin on 0.60× asset turns.
FY25 ROE is 16%, recovered from a FY22 trough of 9% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY25): 14.3% net margin × 0.60× asset turns × 1.87× balance-sheet leverage ≈ 16.0% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 17.2% − 9.5% = a +7.7 pp spread. The 9.5% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. A spread this wide means every dollar reinvested creates more than a dollar of value — the engine compounds.
Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.
Crane Company paid $0.95 per share over the last four reported quarters, up 10.9% on a year ago. The most recent declaration was $0.26 for Mar 26. Against the current price of $197 that is a trailing yield of 0.48%, measured on dividends already paid rather than on a forecast.
Crane Company paid $0.95 per share across the last four reported quarters, most recently $0.26 for Mar 26. That is up 10.9% against the same quarter a year earlier. Against the current price of $197 the trailing twelve months work out to 0.48% — trailing dividends measured against today's price, not a forward estimate.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
Crane Company carries total debt of $1.1 B against shareholder equity of $2.2 B as of Jun 26, a debt-to-equity of 0.50. On the annual view that ratio went from 0.46 in FY21 to 0.56 in FY25. Read the returns elsewhere on this page with that leverage in mind.
Jun 26: total debt of $1.1 B against shareholder equity of $2.2 B — a debt-to-equity of 0.50. On the annual view, debt-to-equity went from 0.46 (FY21) to 0.56 (FY25). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
2.3% of Crane Company's tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 2.9 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 2.3% of the float is sold short, and at typical trading volumes it would take about 2.9 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Crane Company: the Z-score reads 5.57. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 5.57 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 5.57.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Watts Water Technologies, Inc.WTS | 73.0/100Favorable setup81% evidence | FADING | 26.6/35 Revenue 14.3% · PAT 25.3% · OPM change 3.9 pp 83% evidence | 14.3/25 ROCE 5.9% · OPM 19.6% 76% evidence | 13.6/20 P/E 26.3× · PEG 1.04 65% evidence | 18.5/20 RS sector 15.7% · RS bench 5.2% · 1Y 24.1%10 of 12 weeks ahead 100% evidence |
| Exact sum: 26.6 + 14.3 + 13.6 + 18.5 = 73 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Donaldson Company, Inc.DCI | 64.2/100Mixed-positive evidence85% evidence | ASLEEP | 24.7/35 Revenue 4.4% · PAT 20.9% · OPM change 6.3 pp 95% evidence | 14.3/25 ROCE 6.7% · OPM 15.6% 76% evidence | 14.7/20 P/E 23.7× · PEG 0.95 65% evidence | 10.5/20 RS sector -1.2% · RS bench -10.3% · 1Y 6.5%5 of 12 weeks ahead 100% evidence |
| Exact sum: 24.7 + 14.3 + 14.7 + 10.5 = 64.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Nordson CorporationNDSN | 63.5/100Mixed-positive evidence85% evidence | FADING | 19.8/35 Revenue 7.4% · PAT 18.4% · OPM change 1.9 pp 95% evidence | 12.8/25 ROCE 3.6% · OPM 26.6% 76% evidence | 11.7/20 P/E 30.8× · PEG 1.5 65% evidence | 19.2/20 RS sector 16.9% · RS bench 6.2% · 1Y 37.3%5 of 12 weeks ahead 100% evidence |
| Exact sum: 19.8 + 12.8 + 11.7 + 19.2 = 63.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Emerson Electric Co.EMR | 59.2/100Mixed-positive evidence85% evidence | ASLEEP | 21.2/35 Revenue 4.8% · PAT 20.9% · OPM change 2.1 pp 95% evidence | 13.8/25 ROCE 4.2% · OPM 26.9% 76% evidence | 8.9/20 P/E 31.3× · PEG 2.1 65% evidence | 15.3/20 RS sector 6.6% · RS bench -3.1% · 1Y 10.2%6 of 12 weeks ahead 100% evidence |
| Exact sum: 21.2 + 13.8 + 8.9 + 15.3 = 59.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5GE Vernova Inc.GEV | 59.0/100Mixed-positive evidence85% evidence | ASLEEP | 26.8/35 Revenue 13% · PAT 100% · OPM change 1.6 pp 95% evidence | 11.7/25 ROCE 10.9% · OPM 7.5% 76% evidence | 7.0/20 P/E 33.1× · PEG 2.79 65% evidence | 13.5/20 RS sector 14.3% · RS bench 3.8% · 1Y 48.2%1 of 12 weeks ahead 100% evidence |
| Exact sum: 26.8 + 11.7 + 7 + 13.5 = 59 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6IDEX CorporationIEX | 57.3/100Thin evidence · provisional58% evidence | FADING | 18.1/35 Revenue — · PAT — · OPM change 2 pp 45% evidence | 11.4/25 ROCE 3.1% · OPM 19.4% 76% evidence | 10.1/20 P/E 32.7× · PEG — 15% evidence | 17.7/20 RS sector 14.3% · RS bench 3.9% · 1Y 37.6%4 of 12 weeks ahead 100% evidence |
| Exact sum: 18.1 + 11.4 + 10.1 + 17.7 = 57.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 7Rockwell Automation, Inc.ROK | 56.2/100Mixed-positive evidence85% evidence | ASLEEP | 23.7/35 Revenue 11.3% · PAT 13.9% · OPM change 3.2 pp 95% evidence | 14.8/25 ROCE 6.4% · OPM 20.8% 76% evidence | 8.8/20 P/E 46.4× · PEG 1.84 65% evidence | 8.9/20 RS sector 4.2% · RS bench -5.2% · 1Y 19.3%5 of 12 weeks ahead 100% evidence |
| Exact sum: 23.7 + 14.8 + 8.8 + 8.9 = 56.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Illinois Tool Works Inc.ITW | 56.2/100Mixed-positive evidence85% evidence | FADING | 13.8/35 Revenue 4.3% · PAT -5.1% · OPM change 0.3 pp 95% evidence | 17.1/25 ROCE 10.1% · OPM 26.7% 76% evidence | 11.0/20 P/E 24.5× · PEG 1.83 65% evidence | 14.3/20 RS sector 4.3% · RS bench -5.3% · 1Y 2.1%5 of 12 weeks ahead 100% evidence |
| Exact sum: 13.8 + 17.1 + 11 + 14.3 = 56.2 · Decision use: Price leads the evidence: RS versus the benchmark is -5.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 9Dover CorporationDOV | 53.5/100Mixed-positive evidence85% evidence | ASLEEP | 15.5/35 Revenue 7.5% · PAT -50.5% · OPM change 0.7 pp 95% evidence | 17.7/25 ROCE 13.6% · OPM 18.7% 76% evidence | 15.5/20 P/E 26.6× · PEG 0.22 65% evidence | 4.8/20 RS sector -4.2% · RS bench -13.2% · 1Y 9.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.5 + 17.7 + 15.5 + 4.8 = 53.5 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 10AMETEK, Inc.AME | 52.9/100Mixed-positive evidence85% evidence | ASLEEP | 18.4/35 Revenue 12.6% · PAT 9.7% · OPM change -0.2 pp 95% evidence | 13.3/25 ROCE 3.9% · OPM 25.8% 76% evidence | 5.5/20 P/E 35.4× · PEG 3.49 65% evidence | 15.7/20 RS sector 8.8% · RS bench -1.2% · 1Y 23.6%1 of 12 weeks ahead 100% evidence |
| Exact sum: 18.4 + 13.3 + 5.5 + 15.7 = 52.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 11Graco Inc.GGG | 51.7/100Thin evidence · provisional58% evidence | ASLEEP | 16.2/35 Revenue — · PAT — · OPM change -1.8 pp 45% evidence | 15.4/25 ROCE 6.6% · OPM 25.5% 76% evidence | 10.9/20 P/E 24× · PEG — 15% evidence | 9.2/20 RS sector -4.5% · RS bench -13.3% · 1Y -9.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 16.2 + 15.4 + 10.9 + 9.2 = 51.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Otis Worldwide CorporationOTIS | 50.6/100Mixed-positive evidence85% evidence | ASLEEP | 17.2/35 Revenue 5.2% · PAT 0.2% · OPM change -1.1 pp 95% evidence | 19.4/25 ROCE 80.3% · OPM 15.1% 76% evidence | 6.8/20 P/E 18.1× · PEG 4.62 65% evidence | 7.2/20 RS sector -12.7% · RS bench -20.7% · 1Y -22.3%0 of 12 weeks ahead 100% evidence |
| Exact sum: 17.2 + 19.4 + 6.8 + 7.2 = 50.6 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 13Ingersoll Rand Inc.IR | 50.5/100Mixed-positive evidence85% evidence | ASLEEP | 28.0/35 Revenue 7.8% · PAT 44.8% · OPM change 14.6 pp 95% evidence | 10.5/25 ROCE 2.4% · OPM 18.6% 76% evidence | 5.1/20 P/E 33.7× · PEG 5.21 65% evidence | 6.9/20 RS sector -9.3% · RS bench -17.8% · 1Y -12.5%4 of 12 weeks ahead 100% evidence |
| Exact sum: 28 + 10.5 + 5.1 + 6.9 = 50.5 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -9.3% and the one-year return is -12.5%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 14Parker-Hannifin CorporationPH | 50.0/100Mixed-positive evidence85% evidence | FADING | 19.5/35 Revenue 8.3% · PAT 3.3% · OPM change 2.6 pp 95% evidence | 14.3/25 ROCE 5.7% · OPM 23.9% 76% evidence | 4.6/20 P/E 34.3× · PEG 6.75 65% evidence | 11.6/20 RS sector 4.2% · RS bench -5.4% · 1Y 21.6%5 of 12 weeks ahead 100% evidence |
| Exact sum: 19.5 + 14.3 + 4.6 + 11.6 = 50 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 15Xylem Inc.XYL | 49.5/100Mixed-negative evidence85% evidence | ASLEEP | 20.4/35 Revenue 4.5% · PAT 8.5% · OPM change 2.7 pp 95% evidence | 15.4/25 ROCE 9.6% · OPM 17% 76% evidence | 6.9/20 P/E 27.6× · PEG 2.94 65% evidence | 6.8/20 RS sector -13.5% · RS bench -21.4% · 1Y -24.9%1 of 12 weeks ahead 100% evidence |
| Exact sum: 20.4 + 15.4 + 6.9 + 6.8 = 49.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Symbotic Inc.SYM | 47.0/100Mixed-negative evidence67% evidence | TURNING | 26.3/35 Revenue 20.6% · PAT — · OPM change 6.1 pp 71% evidence | 5.8/25 ROCE 3.5% · OPM 4.6% 76% evidence | 8.6/20 P/E 415.7× · PEG — 15% evidence | 6.3/20 RS sector -18.2% · RS bench -25.6% · 1Y -24.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 26.3 + 5.8 + 8.6 + 6.3 = 47 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -18.2% and the one-year return is -24.4%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 17Crane Companythis pageCR | 47.0/100Thin evidence · provisional58% evidence | ASLEEP | 14.0/35 Revenue — · PAT — · OPM change -3.7 pp 45% evidence | 10.8/25 ROCE 5.2% · OPM 14.4% 76% evidence | 9.3/20 P/E 39× · PEG — 15% evidence | 12.9/20 RS sector 5% · RS bench -4.5% · 1Y 8.3%9 of 12 weeks ahead 100% evidence |
| Exact sum: 14 + 10.8 + 9.3 + 12.9 = 47 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 18Gates Industrial Corporation plcGTES | 46.4/100Thin evidence · provisional56% evidence | ASLEEP | 14.9/35 Revenue — · PAT — · OPM change -1.9 pp 39% evidence | 7.3/25 ROCE 2% · OPM 12.9% 76% evidence | 11.1/20 P/E 19.2× · PEG — 15% evidence | 13.1/20 RS sector 5.6% · RS bench -4% · 1Y 0.6%3 of 12 weeks ahead 100% evidence |
| Exact sum: 14.9 + 7.3 + 11.1 + 13.1 = 46.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Eaton Corporation plcETN | 46.1/100Mixed-negative evidence85% evidence | ASLEEP | 13.9/35 Revenue 15.5% · PAT -2.4% · OPM change -1.6 pp 95% evidence | 11.7/25 ROCE 3.7% · OPM 16.3% 76% evidence | 5.3/20 P/E 43.3× · PEG 3.02 65% evidence | 15.2/20 RS sector 7.9% · RS bench -1.8% · 1Y 6.2%3 of 12 weeks ahead 100% evidence |
| Exact sum: 13.9 + 11.7 + 5.3 + 15.2 = 46.1 · Decision use: Price leads the evidence: RS versus the benchmark is -1.8%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 20A. O. Smith CorporationAOS | 44.4/100Thin evidence · provisional58% evidence | ASLEEP | 11.9/35 Revenue — · PAT — · OPM change -1.9 pp 45% evidence | 13.2/25 ROCE 6.5% · OPM 17.1% 76% evidence | 11.5/20 P/E 17.4× · PEG — 15% evidence | 7.8/20 RS sector -10.7% · RS bench -19% · 1Y -22.2%2 of 12 weeks ahead 100% evidence |
| Exact sum: 11.9 + 13.2 + 11.5 + 7.8 = 44.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 21ITT Inc.ITT | 43.2/100Thin evidence · provisional58% evidence | ASLEEP | 11.8/35 Revenue — · PAT — · OPM change -6.3 pp 45% evidence | 8.6/25 ROCE 2.3% · OPM 11.7% 76% evidence | 9.7/20 P/E 34.1× · PEG — 15% evidence | 13.1/20 RS sector 4.2% · RS bench -5.3% · 1Y 7.4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 11.8 + 8.6 + 9.7 + 13.1 = 43.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 22Generac Holdings Inc.GNRC | 43.1/100Thin evidence · provisional58% evidence | ASLEEP | 21.6/35 Revenue — · PAT — · OPM change 2.2 pp 45% evidence | 10.2/25 ROCE 4.8% · OPM 11.1% 76% evidence | 8.8/20 P/E 67.5× · PEG — 15% evidence | 2.5/20 RS sector -9.7% · RS bench -18% · 1Y -3.9%1 of 12 weeks ahead 100% evidence |
| Exact sum: 21.6 + 10.2 + 8.8 + 2.5 = 43.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23Enpro Inc.NPO | 42.6/100Mixed-negative evidence81% evidence | ASLEEP | 11.8/35 Revenue 10.2% · PAT -50% · OPM change -0.9 pp 83% evidence | 6.3/25 ROCE 1.8% · OPM 14.4% 76% evidence | 12.4/20 P/E 123.5× · PEG 0.95 65% evidence | 12.1/20 RS sector 9.2% · RS bench -0.7% · 1Y 27.7%6 of 12 weeks ahead 100% evidence |
| Exact sum: 11.8 + 6.3 + 12.4 + 12.1 = 42.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Flowserve CorporationFLS | 41.2/100Thin evidence · provisional58% evidence | FADING | 14.5/35 Revenue — · PAT — · OPM change -0.3 pp 45% evidence | 8.2/25 ROCE 3.3% · OPM 11.2% 76% evidence | 10.7/20 P/E 26× · PEG — 15% evidence | 7.8/20 RS sector 2.2% · RS bench -7.4% · 1Y 27.6%3 of 12 weeks ahead 100% evidence |
| Exact sum: 14.5 + 8.2 + 10.7 + 7.8 = 41.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 25Pentair plcPNR | 40.2/100Thin evidence · provisional58% evidence | ASLEEP | 15.7/35 Revenue — · PAT — · OPM change 0.2 pp 45% evidence | 11.3/25 ROCE 3% · OPM 20.3% 76% evidence | 11.2/20 P/E 18.9× · PEG — 15% evidence | 2.0/20 RS sector -34.6% · RS bench -40.7% · 1Y -48.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 15.7 + 11.3 + 11.2 + 2 = 40.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26Cummins Inc.CMI | 38.0/100Mixed-negative evidence85% evidence | ASLEEP | 8.4/35 Revenue 2.9% · PAT -7.8% · OPM change -0.7 pp 95% evidence | 11.2/25 ROCE 5.2% · OPM 13.5% 76% evidence | 14.1/20 P/E 36.4× · PEG 0.79 65% evidence | 4.3/20 RS sector -4.1% · RS bench -13% · 1Y 24.5%1 of 12 weeks ahead 100% evidence |
| Exact sum: 8.4 + 11.2 + 14.1 + 4.3 = 38 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 27JBT Marel CorporationJBTM | 37.9/100Mixed-negative evidence74% evidence | ASLEEP | 24.7/35 Revenue 78.2% · PAT — · OPM change 11.2 pp 62% evidence | 5.2/25 ROCE 1% · OPM 7.3% 76% evidence | 4.9/20 P/E 40× · PEG 3.63 65% evidence | 3.1/20 RS sector -16.3% · RS bench -24.1% · 1Y -17.4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 24.7 + 5.2 + 4.9 + 3.1 = 37.9 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -16.3% and the one-year return is -17.4%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 28The Middleby CorporationMIDD | 37.2/100Thin evidence · provisional56% evidence | ASLEEP | 15.9/35 Revenue — · PAT — · OPM change 0 pp 39% evidence | 8.7/25 ROCE 2.4% · OPM 15.9% 76% evidence | 11.4/20 P/E 17.5× · PEG — 15% evidence | 1.2/20 RS sector -17.5% · RS bench -25.2% · 1Y -16.7%1 of 12 weeks ahead 100% evidence |
| Exact sum: 15.9 + 8.7 + 11.4 + 1.2 = 37.2 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 29Regal Rexnord CorporationRRX | 29.7/100Adverse evidence81% evidence | ASLEEP | 14.2/35 Revenue 1.5% · PAT 22% · OPM change -1 pp 83% evidence | 5.5/25 ROCE 1.2% · OPM 10.3% 76% evidence | 8.4/20 P/E 43.5× · PEG 1.94 65% evidence | 1.6/20 RS sector -13.3% · RS bench -21.5% · 1Y 4%1 of 12 weeks ahead 100% evidence |
| Exact sum: 14.2 + 5.5 + 8.4 + 1.6 = 29.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 30Chart Industries, Inc.GTLS | 26.7/100Adverse evidence71% evidence | 4.7/35 Revenue -1.5% · PAT -121.4% · OPM change -9.3 pp 83% evidence | 4.4/25 ROCE 0.7% · OPM 5.9% 76% evidence | 8.5/20 P/E 687.4× · PEG — 15% evidence | 9.1/20 RS sector -3.5% · RS bench -5.2% · 1Y 22.2%0 of 3 weeks ahead to 2026-07-17 100% evidence | |
| Exact sum: 4.7 + 4.4 + 8.5 + 9.1 = 26.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Crane Company's stock price today?
Crane Company trades at $197, +8.3% over the past year. The company is valued at $11.0 B. The stock sits at 53% of its 52-week range of $164–$226, +0.6% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 16 weeks in. — as of 17 September 2026.
What were Crane Company's latest quarterly results?
Crane Company reported revenue of $0.7 B and net profit of $0.1 B for the Mar 26 quarter. Revenue rose 25.0% and profit fell 12.5% year on year. Earnings per share were $1.14. The operating margin was 14.3%, 3.6 pp lower than a year earlier. — as of 17 September 2026.
What is Crane Company's revenue?
Crane Company reported revenue of $0.7 B in the Mar 26 quarter, +25.0% year on year. For the full FY25 fiscal year, revenue was $2.3 B (+8.5%). Over the last 4 years revenue compounded at 2.9% a year. — as of 17 September 2026.
What is Crane Company's profit?
Crane Company earned $0.1 B of net profit in the Mar 26 quarter, −12.5% year on year. Full-year FY25 profit was $0.3 B. The operating margin ran 14.3% in the latest quarter. — as of 17 September 2026.
What is Crane Company's market cap?
Crane Company's market capitalisation is $11.0 B at a stock price of $197. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 17 September 2026.
What is Crane Company's P/E ratio?
Crane Company trades at a P/E of 34.4×, at the 69th percentile of its own 4-year range, against a long-run median of 31.6×. This is a comparison with the stock's own history, not a value call — as of 17 September 2026.
Does Crane Company pay a dividend?
Yes — Crane Company declared $0.26 per share for Mar 26, and $0.95 per share across the last four reported quarters. The latest quarter is up 10.9% on the same quarter a year earlier. — as of 17 September 2026.
What is Crane Company's dividend per share?
Crane Company's most recently declared dividend is $0.26 per share for Mar 26, giving $0.95 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 17 September 2026.
What is Crane Company's dividend yield?
Crane Company's trailing dividend yield is 0.48%: $0.95 declared per share across the last four reported quarters, against a share price of $197. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 17 September 2026.
Is Crane Company overvalued?
On its own history, Crane Company looks expensive: its P/E of 34.4× sits at the 69th percentile of its 4-year range (long-run median 31.6×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 17 September 2026.
Is Crane Company growing?
Not right now — Crane Company's latest numbers are shrinking: latest-quarter revenue +25.0% year on year, profit −12.5%, and the margin −3.6 pp at 14.3%. The 4-year compound rates are 2.9% (revenue) and 13.3% (profit). The earnings engine currently reads: deteriorating — as of 17 September 2026.
How is Crane Company performing?
Crane Company is in a confirmed uptrend, 16 weeks in. Its latest quarter's revenue rose 25.0% and profit fell 12.5% year on year. Against the S&P 500 it has been behind on a trailing-13-week view for 2 weeks. This describes what the data did, not a rating. — as of 17 September 2026.
What stage is Crane Company in?
Topping out — profit and EPS growth have decelerated hard (profit growth +97.4% at its peak → +10.3% latest) while ROCE still reads 15.3%. The read comes from the last 12 quarters of growth (revenue growth +12.4% latest, profit growth +10.3% latest, eps growth −0.5% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 17 September 2026.
Is Crane Company in an uptrend?
Yes — the price is in a confirmed uptrend (week 16 of stage 2), trading +0.6% versus its 200-day average and at 53% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 17 September 2026.
Is Crane Company beating the market?
Not lately — on a trailing-13-week view Crane Company is currently behind the S&P 500 (2 weeks and counting; last ahead the week of 2026-09-04), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 3.5 years the stock moved +164% against the S&P 500's +84% — ahead of the index over the full window. — as of 17 September 2026.
Will Crane Company's stock price go up?
This page publishes no price forecast for Crane Company. What it measures instead: the stock price is $197, the price is in a confirmed uptrend 16 weeks in. Its P/E of 34.4× sits at the 69th percentile of its own 4-year range. — as of 17 September 2026.
Is the market betting against Crane Company?
Somewhat — short interest is 2.3% of Crane Company's tradable float, about 2.9 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 17 September 2026.
Does Crane Company have too much debt?
It is moderate — Crane Company's debt-to-equity is 0.51. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 17 September 2026.
What is Crane Company's capex?
Crane Company spent $0.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $0.1 B. — as of 17 September 2026.
What is Crane Company's cash flow?
Crane Company generated $0.4 B of operating cash flow in FY25 and $0.3 B of free cash flow after $0.1 B of capital spending. Reported profit that year was $0.3 B, so operating cash ran ahead of profit. — as of 17 September 2026.
Is Crane Company's profit real cash?
Mostly — over the last 3 fiscal years, 60% of Crane Company's reported profit arrived as operating cash. In FY25, operating cash was $0.4 B against reported profit of $0.3 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 17 September 2026.
How financially safe is Crane Company?
On the balance sheet, the Z-score reads 5.57 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 17 September 2026.
Where is Crane Company in its business cycle?
Crane Company's FY25 operating margin was 18.2%, against a 5-year band of 0.6%–18.2%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 14.3%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 17 September 2026.
What could break the Crane Company story?
Biggest watch item: margins are the best this company has ever printed — every ratio flatters at record profitability, so the whole story leans on margins holding. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 17 September 2026.
Is Crane Company a stock worth studying right now?
This is not investment advice. The machine read: Crane Company is printing record margins on a fuller multiple. From here the earnings must do all the lifting. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 17 September 2026.
Not SEBI Registered !! Not Investment advice !!